Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor

Yosuke Dotsu 1, Hiroyuki Yamaguchi 1, Minoru Fukuda 1,2,*, Takayuki Suyama 1, Noritaka Honda 1, Yasuhiro Umemiya 1, Hirokazu Taniguchi 3, Hiroshi Gyotoku 1, Shinnosuke Takemoto 1, Ryuta Tagawa 4, Ryosuke Ogata 5, Hiromi Tomono 4, Midori Shimada 5, Hiroaki Senju 5, Katsumi Nakatomi 6, Seiji Nagashima 4, Hiroshi Soda 5, Hiroaki Ikeda 7, Kazuto Ashizawa 2,8 and Hiroshi Mukae 1

1 Department of Respiratory Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8501, Japan; hyamaguchi@nagasaki-u.ac.jp (H.Y.); t-suyama@nagasaki-u.ac.jp (T.S.); maskofstone.n.h@gmail.com (N.H.); msa412u@gmail.com (Y.U.); gyotokuhi@nagasaki-u.ac.jp (H.G.); shinnosuke-takemoto@nagasaki-u.ac.jp (S.T.); hmukae@nagasaki-u.ac.jp (H.M.)
2 Clinical Oncology Center, Nagasaki University Hospital, Nagasaki 852-8501, Japan; ash@nagasaki-u.ac.jp
3 Molecular Pharmacology Program and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; hirokazu_pc@hotmail.com
4 Department of Respiratory Medicine, National Hospital Organization Nagasaki Medical Center, Ohmura 856-8562, Japan; ryuta.tgw@gmail.com (R.T.); tonomohiro@gmail.com (H.T.); nagashima.seiji.kg@mail.hosp.go.jp (S.N.)
5 Department of Respiratory Medicine, Sasebo City General Hospital, Sasebo 857-8511, Japan; suke.820@gmail.com (R.O.); dear_tm_1016_612@yahoo.co.jp (M.S.);
6 Department of Respiratory Medicine, National Hospital Organization Ureshino Medical Center, Ureshino 843-0393, Japan; nktommy-regs@umin.ac.jp
7 Department of Oncology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8523, Japan; hikeda@nagasaki-u.ac.jp
8 Unit of Translational Medicine, Department of Clinical Oncology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8501, Japan

* Correspondence: mifukuda258@nifty.com; Tel./Fax: +81-95-819-7779

Abstract: Background: Single-agent amrubicin chemotherapy is a key regimen, especially for small cell lung cancer (SCLC); however, it can cause severe myelosuppression. Purpose: The purpose of this study was to determine the real-world incidence of febrile neutropenia (FN) among patients treated with single-agent amrubicin chemotherapy for thoracic malignancies. Patients and methods: The medical records of consecutive patients with thoracic malignancies, including SCLC and non-small cell lung cancer (NSCLC), who were treated with single-agent amrubicin chemotherapy in cycle 1 between January 2010 and March 2020, were retrospectively analyzed. Results: One hundred and fifty-six patients from four institutions were enrolled. Their characteristics were as follows: median age (range): 68 (32–86); male/female: 126/30; performance status (0/1/2): 9/108/39; SCLC/NSCLC/others: 111/30/15; and prior treatment (0/1/2/3+): 1/96/31/28. One hundred and thirty-four (86%) and 97 (62%) patients experienced grade 3/4 and grade 4 neutropenia, respectively. One hundred and twelve patients (72%) required therapeutic G-CSF treatment, and 47 (30%) developed FN. The median overall survival of the patients with FN was significantly shorter than that of the patients without FN (7.2 vs. 10.0 months, \( p = 0.025 \)). Conclusions: The real-world incidence rate of FN among patients with thoracic malignancies that were treated with single-agent amrubicin chemotherapy was 30%. It is suggested that prophylactic G-CSF should be administered during the practical use of single-agent amrubicin chemotherapy for patients who have already received chemotherapy.
Keywords: amrubicin; chemotherapy; granulocyte colony-stimulating factor; febrile neutropenia; lung cancer

1. Introduction

Febrile neutropenia (FN) is a major threat to patients that are treated with chemotherapy, as it can result in subsequent hospital admissions, life-threatening infections, treatment delays, and chemotherapy dose reduction. To prevent chemotherapy-related FN, the primary prophylactic use of granulocyte colony-stimulating factor (G-CSF) has been employed. A large-scale meta-analysis of 61 randomized controlled trials of chemotherapy with or without initial G-CSF support revealed that all-cause mortality was lower among patients who received chemotherapy with primary G-CSF support compared to that of without primary G-CSF [1]. The primary prophylactic administration of G-CSF with pegylated granulocyte colony-stimulating factor (PEG-G-CSF) has been approved for the prevention of FN in clinical practice. However, PEG-G-CSF is not used routinely because it is expensive. According to the guidelines developed by the American Society of Clinical Oncology (ASCO) [2], European Organisation for Research and Treatment of Cancer (EORTC) [3], National Comprehensive Cancer Network (NCCN) [4], and Japanese Society of Medical Oncology (JSMO) [5], the prophylactic administration of PEG-G-CSF is recommended during regimens in which the risk of FN is ≥20%.

Amrubicin is a completely synthetic anthracycline derivative, which is characterized by a nine-amino group and a simple sugar moiety. The chemical structure and acute toxicity of amrubicin are similar to those of doxorubicin [6,7]; however, it causes almost no cardiotoxicity [8,9]. Single-agent amrubicin chemotherapy is used to treat small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), and it is especially important as the standard second-line regimen for SCLC [10,11]. As the incidence rate of FN in key clinical trials of single-agent amrubicin chemotherapy was lower than 20%, i.e., 14% and 10%, respectively [10,11], the prophylactic administration of G-CSF is not recommended during single-agent amrubicin therapy. However, single-agent amrubicin can cause severe hematological toxicities, such as grade 4 neutropenia and FN, and is associated with a poor prognosis in the clinical setting. In addition, the incidence rates of FN during single-agent amrubicin chemotherapy varied from 0% to 33% in previous studies [10–24], and the necessity of the prophylactic use of G-CSF in patients that are treated with single-agent amrubicin in real-world settings remains unclear.

Based on these results, we conducted a retrospective multi-institutional study, involving patients with thoracic malignancies that were treated with single-agent amrubicin chemotherapy. The primary objective of the study was to determine the real-world incidence rate of FN in this population.

2. Patients and Methods

2.1. Study Design

This retrospective study was performed at four institutions (Nagasaki University Hospital, Sasebo City General Hospital, National Hospital Organization Nagasaki, and Ureshino Medical Center). The study protocol was reviewed and approved by the ethics committee of each institution. Whenever possible, the fact that the study was being conducted and the purpose of the study were disclosed to the subjects, and they were provided with an opportunity to refuse to participate. This was an independent collaborative (unsponsored) group study.
2.2. Patients and Treatment

The cases of consecutive patients with thoracic malignancies who were treated with single-agent amrubicin between January 2010 and March 2020 were retrospectively analyzed. Medical information regarding the following factors were collected: age; sex; diagnosis; clinical stage; the patients’ history of chemotherapy; the treatment line; the dose of amrubicin (mg/m²); pretreatment renal function; the duration of amrubicin therapy; bone marrow toxicities, including FN, leukopenia, neutropenia, thrombocytopenia, and anemia; urinalysis; the results of biochemical tests of renal and hepatic function and electrolyte levels; the use statuses of G-CSF and antibacterial drugs; progression-free survival (PFS); and overall survival (OS). Filgrastim, lenograstim, and nartograstim were used as therapeutic G-CSF drugs. FN was defined as being present in cases in which the patient experienced a single febrile episode involving fever $\geq 38.0 ^{\circ} C$ and had an absolute neutrophil count (ANC) of $\leq 500$ cells/mm³ (or $\leq 1000$ cells/mm³ with an expected decrease $\leq 500$ cells/mm³). Neutrophil counts were checked each time to determine if a patient had a fever, and clinically expected FNs with only episodes of fever were excluded. Amrubicin was dissolved in 20 mL of normal saline and administered intravenously as a 5 min infusion at a dose of 25–45 mg/mm² on days 1 to 3 every 3–4 weeks. Hematological toxicities were evaluated according to the Common Terminology Criteria for Adverse Events, version 4.03. The data were once collected by the researchers belonging to each hospital, then collected by the central data center, and quality checked, and inquiries about missing items and suspicious sections were addressed. In some cases, the patient was transferred to another hospital during treatment, but we contacted the transferee and collected data. All members were selected as experts who can handle the data properly.

2.3. Statistical Analysis

The primary endpoint was the incidence rate of FN. The secondary endpoints included the duration of hospitalization, whether chemotherapy dose reduction or a treatment delay was required due to hematological adverse events, PFS, and OS. All statistical analyses were performed using IBM SPSS Statistics Advanced, version 27, Japan. Two-sided p-values of $<0.05$ were considered statistically significant. The Kaplan–Meier method was used for the survival analyses of PFS and OS. Welch t and log-rank tests were used for the duration of hospitalization period and survival, respectively. Univariate and multivariate Cox proportional hazards analyses were used for potential risk factors. Progression-free survival was measured from the day chemotherapy commenced until the day the attending physician determined the progression of disease. Overall survival was measured from the day chemotherapy commenced until death by any cause.

3. Results

One hundred and fifty-six patients who received single-agent amrubicin chemotherapy were enrolled in this study. The patients’ baseline characteristics are shown in Table 1. All of the patients were included in the evaluations of toxicity and survival. The prophylactic administration of PEG-G-CSF was not performed in any case. All of the patients except one received amrubicin as a second-line or later treatment, and 111 (71%) of the patients had SCLC. Thirty patients (19%) were administered single-agent amrubicin at a full dose of 45 mg/m², and the others (81%) were given a lower dose from cycle 1 onwards. The most commonly used dose was 35 mg/m² amrubicin.

Table 1. Patient characteristics ($N = 156$).

| Characteristics | Number | (%) |
|-----------------|--------|-----|
| Age, years      | Median | 68  |
| Range           |        | 32–86 |
Female 30 (19)
Male 126 (81)
ECOG PS
0 9 (6)
1 108 (69)
≥2 39 (25)
Histology
Small cell carcinoma 111 (71)
Adenocarcinoma 20 (13)
Mesothelioma 8 (5)
LCNEC 7 (5)
Squamous cell carcinoma 3 (2)
Others 7 (5)
Stage
III 2 (1)
IV 140 (90)
Recurrence 14 (9)
No. of prior chemotherapies
0 1 (1)
1 96 (61)
2 31 (20)
≥3 28 (18)
Neutrophil count (/µL) before AMR therapy
Median 3860
Range 1300–13,500
AMR dose (mg/m²)
25 3 (2)
30 26 (17)
35 70 (45)
40 27 (17)
45 30 (19)

Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; LCNEC, large cell neuroendocrine carcinoma; AMR, amrubicin;

3.1. Toxicity

The hematological toxicities that arose during the treatment are listed in Table 2. The most common grade 3 or worse hematological toxicities were neutropenia and leukocytopenia. One hundred and thirty-nine (89%) patients experienced grade 3 or worse hematological toxicities, and 97 (62%) patients experienced grade 4 toxicities. Forty-seven patients (30%) developed FN (Figure 1A). No treatment-related deaths occurred in this study.
Figure 1. (A) Febrile neutropenia (FN) incidence rate in 156 patients who received single-agent amrubicin chemotherapy. (B) Duration of hospitalization period among patients that received amrubicin chemotherapy with or without febrile neutropenia (FN). (C) Duration of hospitalization period among patients that received amrubicin chemotherapy with or without grade 4 (G4) neutropenia. (D) Duration of hospitalization period among patients that received amrubicin chemotherapy with or without G-CSF. ***: statistically significant difference; G-CSF: granulocyte colony-stimulating factor; CI: confidence interval

Table 2. Hematological toxicities (N = 156).

| Adverse events       | ≥Grade 3 | ≥Grade 4 |
|----------------------|----------|----------|
| Leukopenia           | 111 (71%)| 52 (33%) |
| Neutropenia          | 134 (86%)| 97 (62%) |
| Anemia               | 35 (22%) | 2 (1%)   |
| Thrombocytopenia     | 36 (23%) | 11 (7%)  |
| Febrile neutropenia  | 47 (30%) | -        |

3.2. G-CSF Treatment

Therapeutic G-CSF was administered to 112 (72%) patients due to FN (47 patients, 30%) or severe neutropenia (65 patients, 42%) (Supplement Table S1). Prophylactic PEG-G-CSF was not used in cycle 1 in any case. One patient received prophylactic PEG-G-CSF from cycle 2 onwards because he developed severe neutropenia in cycle 1. He was able to continue receiving amrubicin chemotherapy.

3.3. Outcomes of FN and Severe Neutropenia

As described previously, 47 patients developed FN due to amrubicin chemotherapy. All of them required antibiotic treatment (Supplement Table S2). In addition, 18 patients experienced treatment delays due to FN, and 15 patients required dose reductions from cycle 2 onwards. Fourteen patients had to be switched to the best supportive care due to reductions in their performance statuses. Data regarding the duration of hospitalization
are shown in Figure 1B–D. The duration of hospitalization was significantly longer among the patients who developed FN than among those without FN (29.3 vs. 19.2 days, respectively, \( p < 0.001 \)). The duration of hospitalization was also significantly longer among the patients who experienced severe neutropenia or were treated with therapeutic G-CSF than the patients who did not experience severe neutropenia or were not treated with therapeutic G-CSF.

3.4. Survival Outcomes

The PFS and OS of the patients who received single-agent amrubicin are shown in Figure 2A–H, respectively. The median PFS times of the patients in the FN and non-FN groups were 1.9 (95% confidence interval (CI): 1.3–2.5) and 3.5 (95% CI: 2.4–4.6) months, respectively, and the median PFS time was significantly shorter in the FN group (\( p = 0.003 \)). The median OS times of the patients in the FN and non-FN groups were 7.2 (95% CI: 3.7–10.7) and 10.0 (95% CI: 8.3–11.7) months, respectively, and the median OS time was significantly shorter in the FN group (\( p = 0.025 \)). Neither experiencing grade 4 neutropenia nor being treated with therapeutic G-CSF had a significant impact on PFS or OS. The PFS and OS of 111 patients with SCLC who received single-agent amrubicin are shown in Figure 2I,J, respectively. The median PFS times of the patients who received amrubicin in the FN and non-FN groups were 2.1 and 3.8 months, respectively, and the median PFS time was significantly shorter in the FN group (\( p = 0.021 \)). The median OS times of the patients in the FN and non-FN groups were 7.2 (95% CI: 3.7–10.7) and 10.2 (95% CI: 8.3–11.7) months, respectively, and the median OS time tended to be shorter in the FN group but not significantly different (\( p = 0.072 \)).
Figure 2. Survival curves using the Kaplan–Meier method for patients treated with amrubicin. (A) Progression-free survival curve of all 156 patients. (B) Progression-free survival curve of patients with or without FN. (C) Progression-free survival curve of patients with or without grade 4 (G4) neutropenia. (D) Progression-free survival curve of patients treated with or without G-CSF. (E) Overall survival curve of all 156 patients. (F) Overall survival curve of patients with or without FN. (G) Overall survival curve of patients with or without grade 4 neutropenia. (H) Overall survival curve of patients treated with or without G-CSF. (I) Progression-free survival (PFS) curve and median survival times of 111 small cell lung cancer patients with or without febrile neutropenia (FN). (J) Overall survival (OS) curve of 111 small cell lung cancer patients with or without FN.

3.5. Risk Factors

The potential risk factors of the patients who received single-agent amrubicin for OS were analyzed by univariate Cox proportional hazards and are shown in Table 3. ECOG PS ≥ 2 before treatment and an episode of FN were risk factors for significantly shorter OS in univariate analysis. These two factors and amrubicin dose were analyzed by multivariate Cox proportional hazards and are shown in Table 4. ECOG PS ≥ 2 was a risk factor, but an episode of FN was not in multivariate analysis. A reduction in amrubicin dose of 5 mg/m² before treatment was a risk factor in multivariate analysis. Neither age ≥ 65 nor age ≥ 75 was a risk factor in univariate analysis (Table 3). The potential risk factors of the patients who received single-agent amrubicin for FN were analyzed by Cox proportional hazards and are shown in Table 5 and 6. ECOG PS ≥ 2, neutrophils < 2000/µL, and age ≥ 75 before treatment were risk factors that cause FN at a significantly higher frequency in univariate analysis. ECOG PS ≥ 2, and neutrophils < 2000/µL before treatment were risk factors that cause FN at a significantly higher frequency in multivariate analysis.

Table 3. Potential risk factors for OS by the univariate Cox proportional hazards analysis (N = 156).

| Characteristics | HR     | 95% CI          | p-value |
|-----------------|--------|-----------------|---------|
| Age, years      |        |                 |         |
| <65             | 1      |                 |         |
| ≥65             | 0.815  | 0.552 – 1.204   | 0.305   |
| Age, years      |        |                 |         |
| <75             | 1      |                 |         |
| ≥75             | 0.859  | 0.532 – 1.386   | 0.533   |
| Sex             |        |                 |         |
| Female          | 1      |                 |         |
| Male            | 1.083  | 0.680 - 1.725   | 0.736   |
| Characteristics | HR   | 95% CI        | p-value |
|-----------------|------|---------------|---------|
| **ECOG PS**     |      |               |         |
| 0-1             | 1    |               |         |
| ≥2              | 3.933| 2.395 – 6.458 | <0.001 |
| **Histology**   |      |               |         |
| Small cell carcinoma | 1 |            |         |
| Others          | 1.140| 0.755 – 1.721 | 0.533  |
| **Stage**       |      |               |         |
| IV              | 1    |               |         |
| Recurrence      | 0.935| 0.499 – 1.751 | 0.834  |
| **Prior chemotherapies** | |         |         |
| 0-1             | 1    |               |         |
| ≥2              | 1.178| 0.810 – 1.715 | 0.392  |
| **AMR dose (mg/m²)** | |         |         |
| 45              | 1    |               |         |
| Dose decreased by 5 | 1.731| 0.994 – 3.017 | 0.053  |
| FN              | 1.187| 0.810 – 1.715 | 0.392  |
| **FN**          |      |               |         |
| Non-FN          | 1    |               |         |
| FN              | 1.587| 1.055 – 2.388 | 0.027  |
| **Grade 4 neutropenia** | |         |         |
| Non-G4N         | 1    |               |         |
| G4N             | 1.216| 0.828 - 1.784 | 0.319  |
| GCSF            |      |               |         |
| Without G-CSF   | 1    |               |         |
| With G-CSF      | 1.275| 0.816 – 1.991 | 0.286  |

Abbreviations: OS, Overall Survival; ECOG PS, Eastern Cooperative Oncology Group performance status; AMR, amrubicin; FN, febrile neutropenia; G4N, grade 4 neutropenia.

Table 4. Potential risk factors for OS by the multivariate Cox proportional hazards analysis (N = 156).

| Characteristics | HR   | 95% CI        | p-value |
|-----------------|------|---------------|---------|
| **Age, years**  |      |               |         |
| < 65            | 1    |               |         |
| ≥65             | 0.641| 0.298 – 1.377 | 0.254  |
| **Age, years**  |      |               |         |
| < 75            | 1    |               |         |
| ≥75             | 2.22 | 1.010 – 4.883 | 0.047  |

Abbreviations: OS, Overall Survival; HR, Hazard Ratio; ECOG PS, Eastern Cooperative Oncology Group performance status; AMR, amrubicin; FN, febrile neutropenia.

Table 5. Potential risk factors for FN by the univariate Cox proportional hazards analysis (N = 156).
| Characteristics            | HR  | 95% CI        | p-value |
|---------------------------|-----|---------------|---------|
| ECOG PS                   |     |               |         |
| 0–1                       | 1   |               |         |
| ≥2                        | 3.02| 1.415 – 6.444 | 0.004   |
| Age, years                |     |               |         |
| <75                       | 1   |               |         |
| ≥75                       | 1.713| 0.739 – 3.973 | 0.21    |
| Neutrophils before treatment |   |               |         |
| ≥2000 /µL                | 1   |               |         |
| <2000 /µL                | 3.417| 1.189 – 9.822 | 0.023   |

Abbreviations: FN, febrile neutropenia; ECOG PS, Eastern Cooperative Oncology Group performance status.

Table 6. Potential risk factors for FN by the multivariate Cox proportional hazards analysis (N = 156).

### 4. Discussion

In the present study, the real-world incidence rate of FN among patients that were treated with single-agent amrubicin chemotherapy was found to be 30%, which is higher than the 20% cut-off level for the prophylactic use of PEG-G-CSF recommended in the relevant guidelines. Therefore, it is recommended that prophylactic PEG-G-CSF should be administered during single-agent amrubicin chemotherapy for patients with thoracic malignancies. In addition, the patients who developed FN exhibited significantly shorter PFS in SCLC.

Regarding FN, the incidence rates of FN in 17 prospective clinical trials of single-agent amrubicin therapy, involving 1151 patients with lung cancer, are shown in Table 7.
The total FN incidence rate was 12% (n = 1151, range: 0–33%). The studies conducted in Japan and other countries reported FN incidence rates of 14% (n = 625) and 10% (n = 526), respectively. The FN incidence rates in Japan tended to be higher than those seen in other countries, but the incidence rate of FN was below 20% in both types of studies. The incidence rates of FN among patients with SCLC and NSCLC were 11% (n = 780) and 14% (n = 338), respectively. The FN incidence rates in SCLC tended to be lower than those seen in NSCLC because the former included studies in other countries and first-line treatment. Most guidelines, including the ASCO, EORTC, NCCN, and JSMO guidelines, suggest that the prophylactic administration of G-CSF for regimens that carry a high risk of FN (≥20%) can improve OS, but this is not the case for regimens that carry an intermediate risk of FN (10–20%) [2–5]. Therefore, the prophylactic administration of G-CSF is not currently recommended during single-agent amrubicin chemotherapy. However, we demonstrated that the real-world FN rate was higher than 20%, the patients with FN developed shorter OS, and an episode of FN tends to be a risk factor for shorter OS in the present study. Moreover, the potential risk factors for FN were found to be PS ≥ 2 and neutrophils < 2000/µL via the multivariate Cox proportional hazards analysis. Age ≥ 75 was found to be a potential risk factor for FN via the univariate analysis. The most probable reason for the high frequency of FN in the current study than that previously reported in Table 7 would be whether these were clinical trials or a real-world study. Patients entering clinical trials may have a PS of 0–1 and age restrictions, and are considered to be in good condition. In the actual clinical setting, elderly patients with a PS of 2 and complications present more frequently. We know that there are institutions that provide lung cancer chemotherapy under the policy of not using therapeutic G-CSF. However, we use therapeutic G-CSF when grade 4 neutropenia or FN occurs or is expected to occur, such as on weekends in the current study, so the cause of the high frequency of FN is not due to not using therapeutic G-CSF.

Table 7. Incidence rate of febrile neutropenia after single-agent amrubicin therapy in previous prospective studies (N = 1151) (10–25).

| Author       | Year | Phase | Disease | Number | FN (%) |
|--------------|------|-------|---------|--------|--------|
| Onoda (12)   | 2006 | II    | SCLC    | 60     | 3 (5)  |
| Yana (13)    | 2007 | II    | SCLC    | 33     | 0 (0)  |
| Igawa (14)   | 2007 | II    | SCLC    | 27     | 4 (15) |
| Inoue (10)   | 2008 | II    | SCLC    | 29     | 4 (14) |
| Ettinger (15)| 2010 | II    | SCLC    | 69     | 8 (12) |
| Kaira (16)   | 2010 | II    | SCLC    | 29     | 1 (3)  |
| Jotte (17)   | 2011 | II    | SCLC    | 49     | 5 (10) |
| Pawel (11)   | 2014 | III   | SCLC    | 408    | 41 (10) |
| Murakami (18)| 2014 | II    | SCLC    | 82     | 22 (27) |
| Inoue (19)   | 2015 | II    | SCLC    | 27     | 5 (19) |
| Igawa (20)   | 2008 | II    | NSCLC   | 39     | 2 (5)  |
| Kaneda (21)  | 2010 | II    | NSCLC   | 61     | 18 (30) |
| Kaira (16)   | 2010 | II    | NSCLC   | 37     | 0 (0)  |
| Yoshida (22) | 2011 | II    | NSCLC   | 18     | 6 (33) |
| Kitagawa (23)| 2012 | I     | NSCLC   | 16     | 1 (6)  |
| Yoshioka (24)| 2017 | III   | NSCLC   | 98     | 13 (13) |
| Saigusa (25) | 2019 | II    | NSCLC   | 69     | 9 (13) |
| Total        |      |       |         | 1151   | 142 (12) |

Abbreviations: FN, febrile neutropenia; SCLC, small cell lung cancer; NSCLC, non-small cell lung cancer.

Dosing of amrubicin shows variability in our study; while the full dose of 45 mg/m² was used for 19% of patients, the most commonly used dose was 35 mg/m² because each
attending physician adjusts the dose according to the patient’s condition. This is lower than previous reports of 40 mg/m². Real-world setting studies have shown that doses will be reduced due to an increased proportion of elderly patients (median age 68 years in current study), poor PS (include PS 2 of 25% in current study), and complications compared to previously reported clinical trials. This is considered to be one of the reasons that the FN incidence rate was higher than that of studies in the same country.

Regarding the administration of prophylactic G-CSF in the present real-world study, none of the 156 patients were given prophylactic PEG-G-CSF in the first amrubicin cycle. Even when all cycles are considered, only one patient received prophylactic PEG-G-CSF during single-agent amrubicin treatment (due to severe neutropenia in the previous cycle). In Japan, the hospitalization costs paid to each institution are fixed according to the type of anticancer drug regimen that the patient receives; thus, their income is not affected by whether PEG-G-CSF, which costs JPY 108,635, is administered. This economic factor and the recommendations outlined in the treatment guidelines have contributed to the fact that PEG-G-CSF is not widely administered during single-agent amrubicin chemotherapy in clinical practice. Nevertheless, as revealed in the present study, the prognosis of the patients who developed FN was significantly shortened to a median of 1.9 months for PFS and a median of 7.2 months for OS (compared with 3.5 and 10 months for the patients without FN, respectively), and a randomized phase III study showed that prophylactic G-CSF was effective in reducing the risk of FN and infections in SCLC patients, despite the addition of prophylactic antibiotics [26]; we should consider the administration of prophylactic PEG-G-CSF. Chemotherapy for thoracic malignancies is increasingly being administered in an outpatient setting, and the administration of primary prophylactic G-CSF will enable safer outpatient chemotherapy [27]. On the other hand, it is also important to consider changes in regimen, drug dose, and drug schedule, instead of primary prophylactic administration of G-CSF if the purpose of chemotherapy is symptom relief.

Regarding the myelosuppression encountered in the present study, 86% of the patients that were treated with single-agent amrubicin developed grade 3 or worse neutropenia, and 62% experienced grade 4 neutropenia. Among the patients treated with single-agent amrubicin in previous studies, 39–94% developed grade 3 or worse neutropenia, and 18–79% experienced grade 4 neutropenia [10–19], and efforts are being made to determine appropriate amrubicin doses based on its bone marrow toxicity [28,29]. In studies in which amrubicin was used to treat patients with diseases other than lung cancer, grade 3 or worse neutropenia was reported to occur in 4% of the patients that were treated for thymic tumors and 60% of those that were treated for malignant pleural mesothelioma [30,31]. It might be difficult to complete amrubicin treatment without any problems, as clinicians will want to maintain the standard dose intensity to achieve a strong response. In the current study, 30% of patients developed FN, resulting in longer periods of hospitalization and therapeutic G-CSF and antibiotics being required for longer periods. This suggests that treatment without prophylactic PEG-G-CSF might end up being more expensive, despite the cost of PEG-G-CSF itself being avoided. Furthermore, the development of FN due to amrubicin therapy can adversely affect patients’ performance statuses and quality of life. Thirteen percent of the patients in the present study were unable to receive continuous chemotherapy due to FN. This demonstrated that FN can have an impact on survival in some cases. Consequently, we should consider the prophylactic administration of PEG-G-CSF during single-agent amrubicin chemotherapy for thoracic malignancies.

Regarding the risk factors in the present study, PS ≥ 2 was a risk factor for shorter OS. It is interesting to note that single-agent amrubicin treatment in elderly patients was not a risk factor in the present study, whether they were 65 years or older or 75 years or older. Although chemotherapy in elderly patients is known to have different results than in younger patients [32–34], it is presumed that chemotherapy can safely be administered to even elderly patients with good PS and an appropriate dose setting. An amrubicin dose
of 45 mg/m² was a factor for longer OS, and decrease in dose before treatment was a risk factor. This may be attributed to not only the higher efficacy of the high dose of amrubicin, but also to the attending physician’s belief that the patients had sufficient organ function, were young enough, and had a sufficiently small number of complications to be able to withstand full-dose amrubicin treatment. Patients whose dose of amrubicin is reduced may have same cause, such as poor general condition, which the attending physician considers necessary to reduce the dose. Thus, amrubicin dose is considered to be a confounding factor.

This study had several limitations. First, it was a small-scale investigation conducted at four institutions, and therefore, it was not possible to draw definitive conclusions. However, it can provide some hypotheses for future research. An external validation study involving a larger number of patients might be needed to confirm our findings. Second, this study was only conducted in one country (Japan). The FN rates in Japan tend to be higher than those observed elsewhere, as shown in Table 7, and it is hoped that studies will be conducted in real-world settings in other regions as well. Third, we did not evaluate the cost-effectiveness of using prophylactic PEG-G-CSF. The primary prophylactic use of PEG-G-CSF is expensive compared to therapeutic G-CSF treatment, and this issue should be considered in future.

In conclusion, the real-world incidence rate of FN among patients with thoracic malignancies that were treated with single-agent amrubicin chemotherapy was 30%. It is suggested that prophylactic G-CSF should be administered during the practical use of single-agent amrubicin for patients who have already received chemotherapy.

**Supplementary Materials:** The following are available online at www.mdpi.com/xxxx, Table S1: Administration of therapeutic G-CSF (N = 156); Table S2: Outcomes of febrile neutropenia (N = 47).

**Author Contributions:** Data curation, T.S., N.H., Y.U., H.G., S.T., R.O., H.T. (Hiromi Tomono), M.S., H.S. (Hiroaki Senju), K.N. and S.N.; Writing — original draft, Y.D.; Writing — review & editing, H.Y., M.F., H.T. (Hirokazu Taniguchi), H.S. (Hiroshi Soda), H.I., K.A. and H.M. All authors reviewed the manuscript. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**Institutional Review Board Statement:** The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of Nagasaki University Hospital (No. 20051814, 19 May 2020).

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study.

**Data Availability Statement:** The datasets generated and analyzed during the study are available from the corresponding author on reasonable request.

**Acknowledgments:** We are grateful to the patients and their families for their cooperation in this study. We acknowledge NIH/NCI Cancer Center Support Grant P30 CA008748 (to HT).

**Conflicts of Interest:** The authors declare no conflicts of interest.

**Consent for Publication:** Consent for publication was obtained using the opt-out method from all participants.

**Reference**

1. Lyman, G.H.; Dale, D.C.; Culakova, E.; Poniewierski, M.S.; Wolff, D.A.; Kuderer, N.M.; Huang, M.; Crawford, J. The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: A systematic review and meta-analysis of randomized controlled trials. *Ann. Oncol.* **2013**, *24*, 2475–2484.
2. Smith, T.J.; Khatcheressian, J.; Lyman, G.H.; Ozer, H.; Armitage, J.O.; Balducci, L.; Bennett, C.L.; Cantor, S.B.; Crawford, J.; Cross, S.J.; et al. 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. *J. Clin. Oncol.* **2006**, *24*, 3187–3205.

3. Aapro, M.S.; Bohlius, J.; Cameron, D.A.; Dal Lago, L.; Donnelly, J.P.; Kearney, N.; Lyman, G.H.; Pettengell, R.; Tjan-Heijnen, V.C.; Walewski, J.; et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. *Eur. J. Cancer* **2011**, *47*, 8–32.

4. Crawford, J.; Armitage, J.; Balducci, L.; Becker, P.S.; Blayney, D.W.; Cataland, S.R.; Heaney, M.L.; Hodock, S.; Kloth, D.D.; Kuter, D.J.; et al. Myeloid growth factors. *J. Natl. Compr. Cancer Netw.* **2013**, *11*, 1266–1290.

5. Japanese Society of Medical Oncology. *Practical guideline of febrile neutropenia (FN)*, 2nd ed.; Nankodo Co., Ltd., Tokyo, Japan, 2017; 1–74.

6. Ishizumi, K.; Ohashi, N.; Tanno, N. Stereospecific total synthesis of 9-aminoanthracyclines: (+)-9-amino-9-deoxydaunomycin and related compounds. *J. Org. Chem.* **1987**, *52*, 4477–4485.

7. Morisada, S.; Yanagi, Y.; Kashiwazaki, Y.; Fukui, M. Toxicological aspects of a novel 9-aminoanthracycline, SM-5887. *Ipn. J. Cancer Res.* **1989**, *80*, 77–82.

8. Suzuki, T.; Minamide, S.; Iwasaki, T.; Yamamoto, H.; Kanda, H. Cardiotoxicity of a new anthracycline derivative (SM-5887) following intravenous administration to rabbits: Comparative study with doxorubicin. *Investig. New Drugs* **1997**, *15*, 219–225.

9. Noda, T.; Watanabe, T.; Kohda, A.; Hosokawa, S.; Suzuki, T. Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin cardiomyopathy in beagle dogs. *Investig. New Drugs* **1998**, *16*, 121–128.

10. Inoue, A.; Sugawara, S.; Yamazaki, K.; Maemondo, M.; Suzuki, T.; Gomi, K.; Takanashi, S.; Inoue, C.; Yokouchi, H.; Watanabe, H.; et al. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer. North Japan Lung Cancer Study Group Trial 0402. *J. Clin. Oncol.* **2008**, *26*, 5401–5406.

11. Von Pawel, J.; Kotte, R.; Spigel, D.R.; O’Brien, M.E.R.; Socinski, M.A.; Mezger, J.; Steins, M.; Bosque, L.B.; Bubis, J.; Nackaerts, K.; Trigo, J.M.; et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. *J. Clin. Oncol.* **2014**, *32*, 4012–4019.

12. Onoda, S.; Masuda, N.; Seto, T.; Eguchi, K.; Takiguchi, Y.; Isobe, H.; Okamoto, H.; Ogura, T.; Yokoyama, A.; Seki, N.; et al. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. *J. Clin. Oncol.* **2006**, *24*, 5448–5453.

13. Yana, T.; Negoro, S.; Takada, M.; Yokota, S.; Takada, Y.; Sugiuura, T.; Yamamoto, H.; Sawa, T.; Kawahara, M.; Katakami, N.; et al. Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study. *No. Jpn. J. Cancer Res.* **2007**, *98*, 253–258.

14. Igawa, S.; Yamamoto, N.; Ueda, S.; Ono, A.; Nakamura, Y.; Tsuya, A.; Murakami, H.; Endo, M.; Takahashi, T. Evaluation of the recommended dose and efficacy of amrubicin as second- and third-line chemotherapy for small cell lung cancer. *J. Thorac. Oncol.* **2007**, *2*, 741–744.

15. Ettinger, D.S.; Kotte, R.; Lorigan, P.; Gupta, V.; Garbo, L.; Alemany, C.; Conkling, P.; Spigel, D.R.; Dudek, A.Z.; Shah, C.; et al. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. *J. Clin. Oncol.* **2010**, *28*, 2598–2603.

16. Kaira, K.; Sunaga, Y.; Tomizawa, Y.; Yanagitani, N.; Shimizu, K.; Imai, H.; Utsugi, M.; Iwasaki, Y.; Iijima, H.; Tsurumaki, H.; et al. A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer. *Lung Cancer* **2010**, *69*, 99–104.

17. Kotte, R.; Conkling, P.; Reynolds, C.; Galsky, M.D.; Klein, L.; Fitzgibbon, J.F.; McNally, R.; Renschler, M.F.; Oliver, J.W. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. *J. Clin. Oncol.* **2011**, *29*, 287–293.

18. Murakami, H.; Yamamoto, N.; Shibata, T.; Takeda, K.; Ichinose, Y.; Ohe, Y.; Yamamoto, N.; Takeda, Y.; Kudoh, S.; Atagi, S.; et al. A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japanese Clinical Oncology Group Study (JCOG0901). *Lung Cancer* **2014**, *84*, 67–72.

19. Inoue, A.; Sugawara, S.; Maemondo, M.; Mori, Y.; Ozumi, S.; Harada, M.; Taima, K.; Morikawa, N.; Ishida, T.; Kinoshita, I.; et al. Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0702. *Lung Cancer* **2015**, *89*, 61–65.

20. Igawa, S.; Takahashi, T.; Nakamura, Y.; Tsuya, A.; Ono, A.; Shukuya, T.; Murakami, H.; Endo, M.; Yamamoto, N. Efficacy of amrubicin for non-small cell lung cancer after failure of two or more prior chemotherapy regimens. *Anticancer Res.* **2008**, *28*, 3855–3858.

21. Kaneda, H.; Okamoto, I.; Hayashi, H.; Yoshioka, H.; Miyazaki, M.; Kudoh, S.; Kimura, T.; Sugitani, S.; Sawa, T.; Takeda, K.; et al. Phase II trial of amrubicin for second-line treatment of advanced non-small cell lung cancer: Results of the West Japan Thoracic Oncology Group trial (WJTOG0404). *J. Thorac. Oncol.* **2010**, *5*, 105–109.

22. Yoshida, H.; Sekine, I.; Tsuta, K.; Horinouchi, H.; Nokihara, H.; Yamamoto, N.; Kubota, K.; Tamura, T. Amrubicin monotherapy for patients with previously treated advanced large-cell neuroendocrine carcinoma of the lung. *Jpn. J. Clin. Oncol.* **2011**, *41*, 897–901.
23. Kitagawa, C.; Saka, H.; Kajikawa, S.; Mori, K.; Oki, M.; Suzuki, R. Phase I and pharmacologic study of weekly amrubicin in patients with refractory or relapsed lung cancer: Central Japan Lung Study Group (CJLSG). *Cancer Cheother. Pharmacol.* 2012, 69, 1379–1385.

24. Yoshioka, H.; Katakami, N.; Okamoto, H.; Iwamoto, Y.; Seto, T.; Takahashi, T.; Sunaga, N.; Kudoh, S.; Chikamori, K.; Harada, M.; et al. A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer. *Ann. Oncol.* 2017, 28, 285–291.

25. Saigusa, M.; Asada, K.; Akamatsu, T.; Tanaka, Y.; Endo, Y.; Yamamoto, A.; Morita, S.; Shirai, T. Efficacy and safety of amrubicin in non-small-cell lung cancer patients beyond third-line therapy. *Oncol. Res. Treat.* 2019, 42, 52–56.

26. Timmer-Bonte, J.N.; de Boo, T.M.; Smit, H.J.; Bisma, B.; Wilschut, F.A.; Cheragwandi, S.A.; Termeer, A.; Hensing, C.A.; Akkermans, J.; Adang, E.M.; et al. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: A dutch randomized phase III study. *J. Clin. Oncol.* 2005, 23, 7974–7984.

27. Fukuda, M.; Yamaguchi, H.; Takemoto, S.; Senju, H.; Gyotoku, H.; Dotsu, Y.; Umeyama, Y.; Tsuchiya, A.; Ikeda, T.; Nose, S.; et al. Trends in outpatient chemotherapy for thoracic oncology. *Gan Kagaku Ryoho. Cancer Chemother.* 2020, 47, 1461–1414. (In Japanese)

28. Kaira, K.; Sunaga, N.; Imai, H.; Kamide, Y.; Koga, Y.; Ono, A.; Kuwako, T.; Masuda, T.; Hisada, T.; Ishizuka, T.; et al. Phase I dose escalation study of amrubicin plus paclitaxel in previously treated advanced non-small cell lung cancer. *Int. J. Clin. Oncol.* 2016, 21, 240–247.

29. Shimada, M.; Yamaguchi, H.; Fukuda, M.; Tomono, H.; Honda, N.; Dotsu, Y.; Taniguchi, H.; Gyotoku, H.; Senju, H.; Takemoto, S.; et al. Dose escalation study of amrubicin and cisplatin with concurrent thoracic radiotherapy for limited-disease small cell lung cancer. *Cancer Chemother. Pharmacol.* 2019, 84, 1059–1064.

30. Hellyer, J.A.; Gubens, M.A.; Cunanan, K.M.; Padda, S.K.; Burns, M.; Spittler, A.J.; Riess, J.W.; Pedro-Salcedo, M.S.; Ramchandran, K.J.; Neal, J.W.; et al. Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies. *Lung Cancer* 2019, 137, 71–75.

31. Ikeda, T.; Takemoto, S.; Senju, H.; Gyotoku, H.; Taniguchi, H.; Shimada, M.; Dotsu, Y.; Umeyama, Y.; Tomono, H.; Kitazaki, T.; et al. Amrubicin in previously treated patients with malignant pleural mesothelioma: A phase II study. *Thorac. Cancer* 2020, 11, 1972–1978.

32. Abe, T.; Takeda, K.; Ohe, Y.; Kudoh, S.; Ichinose, Y.; Okamoto, H.; Yamamoto, N.; Yoshioka, H.; Minato, K.; Sawa, T.; et al. Randomized phase III trial comparing weekly docetaxel plus cisplatin versus docetaxel monotherapy every 3 weeks in elderly patients with advanced non-small-cell lung cancer: The intergroup trial JCOG0803/WJOG4307L. *J. Clin. Oncol.* 2015, 33, 575–581.

33. Fukuda, M.; Kitazaki, T.; Ogasawara, D.; Ichiki, M.; Mukae, H.; Maruyama, R.; Nakagaki, N.; Shimada, M.; Ikeda, T.; Kishimoto, J.; et al. Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyusyu (LOGIK1201). *Lung Cancer* 2019, 132, 1–8.

34. Takemoto, S.; Nakamura, Y.; Fukuda, M.; Senju, H.; Gyotoku, H.; Taniguchi, H.; Shimada, M.; Ikeda, T.; Yamaguchi, H.; Nakatomi, K.; et al. Phase I study of pemetrexed and concurrent radiotherapy for previously untreated elderly patients with locally advanced non-squamous non-small cell lung cancer. *Thorac. Cancer* 2017, 8, 577–581.